← Back to Screener
Jazz Pharmaceuticals, Inc. (JAZZ)
Price$197.83
Favorite Metrics
Price vs S&P 500 (26W)40.69%
Price vs S&P 500 (4W)4.64%
Market Capitalization$12.22B
P/E Ratio (Annual)19.93x
All Metrics
P/CF (Annual)9.01x
Book Value / Share (Quarterly)$70.30
P/TBV (Annual)6.28x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.26%
Cash Flow / Share (Quarterly)$18.65
Price vs S&P 500 (YTD)14.61%
Gross Margin (TTM)88.21%
Net Profit Margin (TTM)-8.35%
EPS (TTM)$-5.85
10-Day Avg Trading Volume0.89M
EPS Excl Extra (TTM)$-5.85
Revenue Growth (5Y)12.54%
EPS (Annual)$-5.84
ROI (Annual)-3.68%
Gross Margin (Annual)88.21%
Net Profit Margin (5Y Avg)-0.11%
Cash / Share (Quarterly)$39.75
Revenue Growth QoQ (YoY)10.09%
EPS Growth (5Y)-1.36%
P/E Normalized (Annual)19.93x
ROA (Last FY)-3.05%
Revenue Growth TTM (YoY)4.88%
EBITD / Share (TTM)$3.67
ROE (5Y Avg)0.19%
Operating Margin (TTM)-10.08%
Cash Flow / Share (Annual)$18.65
P/B Ratio2.83x
P/B Ratio (Quarterly)2.39x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.79x
Net Interest Coverage (TTM)-2.18x
ROA (TTM)-3.13%
EPS Growth QoQ (YoY)7.21%
EV / EBITDA (TTM)72.14x
EPS Incl Extra (Annual)$-5.84
Current Ratio (Annual)1.86x
Quick Ratio (Quarterly)1.60x
3-Month Avg Trading Volume0.98M
52-Week Price Return95.90%
EV / Free Cash Flow (Annual)14.13x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$29.63
P/S Ratio (Annual)2.86x
Asset Turnover (Annual)0.37x
52-Week High$202.57
Operating Margin (5Y Avg)5.27%
EPS Excl Extra (Annual)$-5.84
CapEx CAGR (5Y)-11.17%
Tangible BV CAGR (5Y)42.31%
26-Week Price Return44.67%
Quick Ratio (Annual)1.60x
13-Week Price Return21.78%
Total Debt / Equity (Annual)1.24x
Current Ratio (Quarterly)1.86x
Enterprise Value$16,190.275
Revenue / Share Growth (5Y)10.84%
Asset Turnover (TTM)0.38x
Book Value / Share Growth (5Y)1.47%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.12x
Pretax Margin (Annual)-14.71%
Cash / Share (Annual)$39.75
3-Month Return Std Dev35.74%
Gross Margin (5Y Avg)87.38%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-18.72%
EBITDA Interim CAGR (5Y)12.02%
ROE (Last FY)-8.25%
Net Interest Coverage (Annual)-2.18x
EPS Basic Excl Extra (Annual)$-5.84
P/FCF (TTM)10.66x
Receivables Turnover (TTM)5.52x
EV / Free Cash Flow (TTM)14.13x
Total Debt / Equity (Quarterly)1.24x
EPS Incl Extra (TTM)$-5.85
Receivables Turnover (Annual)5.52x
ROI (TTM)-3.79%
P/S Ratio (TTM)2.86x
Pretax Margin (5Y Avg)-1.84%
Revenue / Share (Annual)$69.98
Tangible BV / Share (Annual)$26.16
Forward P/E8.22x
Free OCF CAGR (5Y)17.11%
Price vs S&P 500 (52W)66.07%
Year-to-Date Return17.25%
5-Day Price Return0.60%
EPS Normalized (Annual)$-5.84
ROA (5Y Avg)0.10%
Net Profit Margin (Annual)-8.35%
Month-to-Date Return5.44%
Cash Flow / Share (TTM)$10.05
EBITD / Share (Annual)$3.68
Operating Margin (Annual)-10.08%
LT Debt / Equity (Annual)1.00x
P/CF (TTM)9.01x
ROI (5Y Avg)0.07%
LT Debt / Equity (Quarterly)1.00x
EPS Basic Excl Extra (TTM)$-5.85
P/TBV (Quarterly)5.48x
P/B Ratio (Annual)2.39x
Inventory Turnover (TTM)1.12x
Pretax Margin (TTM)-14.71%
Book Value / Share (Annual)$70.30
Price vs S&P 500 (13W)21.09%
Net Margin Growth (5Y)-10.67%
Beta0.26x
P/FCF (Annual)10.66x
Revenue / Share (TTM)$69.89
ROE (TTM)-8.82%
52-Week Low$97.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.26
4.26
4.26
4.26
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
JAZZJazz Pharmaceuticals, Inc. | 2.86x | 4.88% | 88.21% | -1.36% | $197.83 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical company with approved treatments in neuroscience and oncology. Its portfolio of nine drugs includes leading franchises such as Xyrem/Xywav for narcolepsy, Epidiolex for severe epilepsy (acquired in 2021 from GW Pharmaceuticals), and oncology medications including Zepzelca, Rylaze, and Vyxeos. The company focuses on high-unmet-need therapeutic areas with limited competitive options.